LAUSR

BACKGROUND Patients with schizophrenia display a very high rate of smoking in comparison with the general population. The aim of the present meta-analysis was to assess the association between cognitive performances and smoking status in patients with schizophrenia. METHODS This review was registered at PROSPERO, number CRD42019126758. After a systematic search on MEDLINE, PsycINFO, and clinicaltrials.gov databases, all studies measuring neurocognitive performances in both smoking and nonsmoking patients with a diagnosis of schizophrenia were included. Original data were extracted. Standardized mean differences (SMD) were calculated with the means and standard deviations extracted using a random-effect model. Cognitive performances were compared between smoking and nonsmoking patients with schizophrenia. Meta-regressions were performed to explore the influence of sociodemographic and clinical variables on SMD. RESULTS Eighteen studies were included in this meta-analysis. Chronic smoking in patients with schizophrenia, compared to nonsmoking, was associated with a significant more important impairment in attention (p = 0.02), working memory (p < 0.001), learning (p < 0.001), executive function (EF) reasoning/problem solving (p < 0.001) and speed of processing (p < 0.001), but not in delayed memory, EF abstraction/shifting, EF inhibition and language. The meta-regression analysis found that attention impairment could be influenced by age (p < 0.001) and Positive and Negative Syndrome Scale (PANSS) total score (p = 0.006). CONCLUSIONS This meta-analysis provides strong evidence that, in patients with schizophrenia, chronic smoking is related to cognitive impairment. This association emphasizes the importance of paying careful attention to both tobacco addiction and cognitive functioning in patients with schizophrenia.